BioArctic AB's (BIOA-B.ST) partner Eisai (4523.T) announced that they have filed a new drug application for Leqembi or lecanemab for a subcutaneous formulation as a new route of administration to Japan's Pharmaceuticals and Medical Devices Agency. The application is based on data from multiple subcutaneous administration sub-studies of lecanemab conducted as part of the Phase 3 Clarity AD open-label extension, following the 18-month core study in individuals with Mild Cognitive Impairment due to Alzheimer's disease or mild stage of AD dementia.
Leqembi is the result of a collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.